Equity Sector Funds Very High Risk
To generate long-term capital appreciation by creating a portfolio that is invested in Equity and Equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
However there can be no assurance that the investment objectives of the scheme will be realized.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | 9.18% | 6.67% | -0.99% | -3.59% | 7.1% | 14.08% | 27.02% | 19.69% | 16.23% | 0% | 19.44% |
| Category returns | 6.83% | 7.45% | 0.03% | -2.3% | 6.38% | 11.92% | 22.96% | 16.06% | 13.74% | 12.95% | N/A |
| Absolute returns | 7.92% | 9.59% | 3.23% | 3.36% | 10.25% | 35.81% | 114.84% | 127.21% | 113.75% | 0% | 318.3% |
| Rank within category | 1 | 12 | 13 | 12 | 6 | 4 | 1 | 1 | 1 | 5 | N/A |
| Total Schemes in Category | 18 | 18 | 17 | 17 | 16 | 14 | 10 | 10 | 9 | 4 | N/A |
| Sector Funds | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Yearly returns | N/A | 4.66% | 71.37% | 18.23% | -8.5% | 41.31% | 48.14% | -0.8% | 5.07% |
| Q1 returns | N/A | 2.63% | -7.74% | -2.09% | -6.01% | -2.76% | 11.48% | -9.79% | -8.04% |
| Q2 returns | N/A | -4.93% | 37.11% | 17.81% | -8.79% | 16.95% | 6.66% | 8.81% | 14.26% |
| Q3 Returns | N/A | -2.39% | 22.32% | 4.01% | 6.63% | 11.79% | 21.11% | -1.19% | N/A |
| Q4 Returns | -5.36% | 9.88% | 10.75% | -1.46% | 0.1% | 11.16% | 2.87% | 2.29% | N/A |
Expense ratio: 2.41%
Inclusive of GST
Exit load
1% on or before 15D, Nil after 15D
| Alpha | 1.33477 |
| Beta | 0.7383 |
| Sharpe Ratio | 0.401992 |
| Sortino Ratio | 0.902946 |
| R-Squared | 0.3775 |
| Tracking Error | 3.4389 |
| Downside Risk | 15.8897 |
| Std. Deviation (Annualised) | 14.5645 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth Current | 9.18% | 6.67% | -0.99% | -3.59% | 7.1% | 27.02% | 16.23% | 0% | 19.44% | 6,293.14 | 1.87 | 0.39 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | 7.91% | 7.54% | 0.1% | -2.35% | 8.33% | 24.87% | 13.99% | 12.81% | 14.66% | 1,055.53 | 2.28 | 0.35 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | 5.71% | 8.21% | 0.45% | -1.13% | 4.56% | 24.83% | 15.56% | 12.3% | 16.26% | 4,063.64 | 1.93 | 0.37 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | 6.15% | 10.25% | 3.03% | 0.11% | 9.4% | 23.81% | 14.41% | 0% | 19.42% | 2,753.72 | 1.94 | 0.34 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | 4.7% | 6.4% | 1.22% | -1.71% | 5.37% | 22.75% | 12.57% | 0% | 18.41% | 858.87 | 2.30 | 0.33 | Very High |
| Nippon India Pharma Fund - Growth | 5.58% | 6.09% | 0.67% | -3.68% | 4.04% | 22.1% | 13.33% | 14.48% | 19.73% | 7,898.24 | 1.82 | 0.32 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | 6.85% | 5.21% | -3.15% | -4.34% | 2.3% | 22.03% | 13.39% | 12.21% | 11.21% | 1,229.42 | 2.15 | 0.30 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | 8.21% | 4.38% | -0.83% | -4.8% | 4.87% | 21.77% | 13.64% | 0% | 20.1% | 2,891.76 | 1.94 | 0.31 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | 7.33% | 7.14% | -1.96% | -3.4% | 4.69% | 20.94% | 10.57% | 0% | 16.19% | 78.30 | 2.36 | 0.29 | Very High |
| ITI Pharma & Healthcare Fund - Regular Plan - Growth | 8.1% | 8.47% | -2.98% | -5.82% | 0.32% | 19.48% | 0% | 0% | 10.95% | 211.30 | 2.35 | 0.25 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 96.76% |
| Cash & Cash Equivalents and Net Assets | 3.24% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 81.92% | |
| Retailing | 5.09% | |
| Healthcare Services | 6.69% | |
| Others | 3.24% | |
| Insurance | 1.25% | |
| Chemicals & Petrochemicals | 1.15% | |
| Healthcare Equipment & Supplies | 0.66% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 11.76% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.15% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.58% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.06% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.94% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.81% |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.44% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.80% |
| Medplus Health Services Ltd. | Retailing | Domestic Equities | 3.37% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.24% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 3.09% |
| TREPS | Cash & Cash Equivalents and Net Assets | 2.19% | |
| Akums Drugs & Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.02% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.96% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.93% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.88% |
| Thyrocare Technologies Ltd. | Healthcare Services | Domestic Equities | 1.88% |
| JB Chemicals & Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.77% |
| Alembic Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.74% |
| Alivus Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.72% |
| Entero Healthcare Solutions Ltd. | Retailing | Domestic Equities | 1.72% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.51% |
| Blue Jet Healthcare Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.44% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.36% |
| Metropolis Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.31% |
| Medi Assist Healthcare Services Ltd. | Insurance | Domestic Equities | 1.25% |
| Fine Organic Industries Ltd. | Chemicals & Petrochemicals | Domestic Equities | 1.15% |
| Hikal Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.14% |
| Windlas Biotech Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.10% |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | 1.05% | |
| Aarti Drugs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.04% |
| Sanofi Consumer Healthcare India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.03% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.90% |
| Astrazeneca Pharma India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.72% |
| FDC Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.66% |
| Laxmi Dental Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.66% |
| Shilpa Medicare Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.61% |
| Nephrocare Health Services Ltd. | Healthcare Services | Domestic Equities | 0.42% |
| Sun Pharma Advanced Research Company Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.38% |
| Senores Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.21% |
| Cash Margin - Derivatives | Cash & Cash Equivalents and Net Assets | 0.01% | |
| Total | 100.00% |
RETURNS
It is an Open ended scheme that primarily invests in Sector Funds.
To generate long-term capital appreciation by creating a portfolio that is invested in Equity and Equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
However there can be no assurance that the investment objectives of the scheme will be realized.
The scheme benchmark is the BSE Health Care - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 10.25%
3-year: 29%
5-year: 16.4%
Top holdings include names such as:
The NAV is around ₹41.83 (approx.) for the ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth.
The fund’s AUM is approximately ₹6,669 Cr.
The expense ratio for the Regular Plan is 2.41.
1% on or before 15D, Nil after 15D.
Minimum SIP starts at ₹1000.
The minimum lump sum investment is ₹5000. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund manager: Dharmesh Kakkad
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
